Cytokinetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Cytokinetics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. 

CEO
Robert I. Blum
CEORobert I. Blum
Employees
673
Employees673
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
1997
Founded1997
Employees
673
Employees673

CYTK Key Statistics

Market cap
10.46B
Market cap10.46B
Price-Earnings ratio
-11.89
Price-Earnings ratio-11.89
Dividend yield
Dividend yield
Average volume
1.94M
Average volume1.94M
High today
$83.03
High today$83.03
Low today
$75.81
Low today$75.81
Open price
$78.79
Open price$78.79
Volume
2.52M
Volume2.52M
52 Week high
$88.31
52 Week high$88.31
52 Week low
$32.89
52 Week low$32.89

Stock Snapshot

With a market cap of 10.46B, Cytokinetics(CYTK) trades at $81.78. The stock has a price-to-earnings ratio of -11.89.

During the trading session on 2026-08-07, Cytokinetics(CYTK) shares reached a daily high of $83.03 and a low of $75.81. At a current price of $81.78, the stock is +7.9% higher than the low and still -1.5% under the high.

Trading activity shows a volume of 2.52M, compared to an average daily volume of 1.94M.

Over the past 52 weeks, Cytokinetics(CYTK) stock has traded between a high of $88.31 and a low of $32.89.

Over the past 52 weeks, Cytokinetics(CYTK) stock has traded between a high of $88.31 and a low of $32.89.

CYTK News

Investing.com 8h
Earnings call transcript: Cytokinetics tops Q2 2026 estimates on MYQORZO launch - Investing.com

...

Earnings call transcript: Cytokinetics tops Q2 2026 estimates on MYQORZO launch - Investing.com
TipRanks 11h
Cytokinetics reports Q2 EPS ($1.50), consensus ($1.60)

Reports Q2 revenue $28.62M, consensus $17.46M. “Our second quarter results demonstrate commercial launch momentum for MYQORZO alongside continued excellence for...

Analyst ratings

91%

of 23 ratings
Buy
91.3%
Hold
8.7%
Sell
0%

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.